Engineered α-Synuclein-specific nanobody CAR iTregs restrain neuroinflammation and proteinopathy in Parkinson’s disease mice

Alice Calderoni Melania Nannoni Giorgia Ruffini Matteo Doglio Clara Bercher Brayer Giannelli Sea Serena R. Melki M. Casucci C. Bonini Sharon Muggeo V. Broccoli

Aug 2026 · bioRxiv · 0 citations

Biology

TL;DR

It is demonstrated that αSyn-specific CAR iTregs can selectively exert potent local immunomodulatory effects, establishing a promising antigen-specific cellular immunotherapy platform for PD and other synucleinopathies.

DOI Semantic Scholar

View source

Similar papers

Open access Sep 2026

Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo

Parkinson’s disease (PD), the most prevalent neurodegenerative movement disorder, is characterised by widespread alpha-synuclein (α-Syn) pathology in the brain and the progressive degeneration of nigrostriatal dopaminergic neurons. Experimental and clinicopathological data support a templated, prion-like component to α...

James M. Hennegan, Michael J. Hurley, Matthew P. Colley et al. · Acta Neuropathologica · 0 citations

Open access Sep 2026

Cellular prion protein levels modulate nigrostriatal vulnerability to α-synuclein oligomers in Parkinson’s disease

PrPC expression levels are identified as an important modulator of nigrostriatal vulnerability and neuroinflammatory phenotype in response to αSynO, supporting the hypothesis that PrPC contributes to αSynO-mediated pathogenic mechanisms.

Flavio de Souza Júnyor, F. Leser, Sarah de Souza Albuquerque et al. · Frontiers in Neuroscience · 0 citations

Open access Oct 2026

Human microglia clear intraneuronal α-synuclein aggregates by GPNMB-mediated trogocytosis

This study identifies a subtype of human microglia capable of removing intraneuronal aggregates and potential therapeutic targets and identifies a cluster of disease-associated microglia responsible for this beneficial phenotype and the Parkinson's disease GWAS candidate glycoprotein nonmetastatic melanoma protein B (G...

Hung-Ju Chueh, Antigoni Katsikoudi, Ana Aragón-González et al. · Science Translational Medici... · 0 citations

Review Aug 2026

Rebalancing α-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson’s Disease

It is proposed that a systems-level approach can be taken where PD is understood as a disease characterized by the imbalance in proteostasis, and potential treatment modalities include small molecules targeting lysosome function, CMA enhancers, gene therapy, and antibodies against extracellular α-synuclein.

Maryam Jabeen, Huma Hameed, Syed Muhammad Ahmad et al. · Neuromolecular medicine · 0 citations

Sep 2026

Biologically-synthesized zinc oxide nanoparticle-based α-synuclein nanoformulation mitigates Parkinson's disease progression in Drosophila melanogaster.

Parkinson's disease (PD) is a synucleinopathy characterized by the accumulation of alpha-synuclein (αS) amyloid aggregates and loss of dopaminergic neurons. Evidence suggests that PD originates in intestine and progresses to brain via the vagus nerve. Thus, initially, the potential of orally-fed αS pre-formed fibrils (...

Sonali Jena, K. Subham, Harshit Kalra et al. · International Journal of Bio... · 0 citations

Open access Oct 2026

PODXL regulates the neuronal entry of α-synuclein aggregates

Cell-to-cell transmission of α-synuclein (α-Syn) aggregates is a key event in Parkinson’s disease (PD) pathogenesis, yet the neuronal surface factors that govern uptake of pathogenic α-Syn fibrils remain undefined. We developed a flow cytometry-based CRISPR activation screen for modifiers of α-Syn preformed fibril (PFF...

Sandesh Neupane, Lea Šustić, Lorenzo Maraio et al. · bioRxiv · 0 citations